In the Claims

1.-22. (Cancelled)

23. (Previously Presented) A pharmaceutical composition comprising:

a pharmaceutically acceptable agent; and

a compound selected from one of Formula I and Formula II, and pharmaceutically acceptable salts thereof:



Formula I



Formula II

where Formulae I and II include all possible geometric, racemic, diasteriomeric, and enantiomeric forms and where:

R^1 is selected from H, $(C_1\text{-}C_6)$alkyl, $(C_3\text{-}C_6)$cycloalkyl-$(C_1\text{-}C_6)$alkyl, $(C_3\text{-}C_6)$cycloalkyl-$(C_1\text{-}C_6)$alkenyl, aryl and azaaromatic;

R^2 is selected from hydrogen, $(C_1\text{-}C_6)$alkyl, $(C_2\text{-}C_6)$alkene, and $(C_2\text{-}C_6)$alkynyl, and in Formula I, R^2 may additionally be selected from O= or HN=;

R^3 is selected from hydrogen, $(C_1\text{-}C_6)$alkyl, $(C_3\text{-}C_6)$cycloalkyl, $(C_2\text{-}C_6)$alkenyl, aryl, and aryl$(C_1\text{-}C_6)$alkyl; and

R^4 is $(C_1\text{-}C_6)$alkyl, and $(C_3\text{-}C_6)$cycloalkyl; and R^5 is aryl or azaaromatic and may form a bond to R^1 to result in a conjugated ring system;

in an amount is sufficient to induce analgesia and/or deter abuse of abusive substances.

24. (Previously Presented) The composition of claim 23, wherein R^1 is selected from the group consisting of aryl and azaaromatic, each having 1-5 substituents independently selected from the group consisting of hydrogen, $(C_1\text{-}C_6)$alkyl, $(C_3\text{-}C_6)$cycloalkyl, $(C_2\text{-}C_6)$alkenyl, aryl, aryl$(C_1\text{-}C_6)$alkyl, N-methylamino, N,N-dimethylamino, carboxylate, $(C_1\text{-}C_3)$alkylcarboxylate, carboxaldehyde, acetoxy, propionyloxy, isopropionyloxy, cyano, aminomethyl, N-methylaminomethyl, N,N-dimethylaminomethyl, carboxamide, N-methylcarboxamide, N,N-dimethylcarboxamide, acetyl, propionyl, formyl, benzoyl, sulfate, methylsulfate, hydroxyl,

methoxy, ethoxy, propoxy, isopropoxy, thiol, methylthio, ethylthio, propiothiol, fluoro, chloro, bromo, iodo, trifluoromethyl, propargyl, nitro, carbamoyl, ureido, azido, isocyanate, thioisocyanate, hydroxylamino, and nitroso.

25. (Previously Presented) The composition of claim 23, wherein R^5 is selected from the group consisting of aryl and azaaromatic, each having 1-5 substituents independently selected from the group consisting of hydrogen, $(C_1\text{-}C_6)$alkyl, $(C_3\text{-}C_6)$cycloalkyl, $(C_2\text{-}C_6)$alkenyl, aryl, aryl$(C_1\text{-}C_6)$alkyl, N-methylamino, N,N-dimethylamino, carboxylate, $(C_1\text{-}C_3)$alkylcarboxylate, carboxaldehyde, acetoxy, propionyloxy, isopropionyloxy, cyano, aminomethyl, N-methylaminomethyl, N,N-dimethylaminomethyl, carboxamide, N-methylcarboxamide, N,N-dimethylcarboxamide, acetyl, propionyl, formyl, benzoyl, sulfate, methylsulfate, hydroxyl, methoxy, ethoxy, propoxy, isopropoxy, thiol, methylthio, ethylthio, propiothiol, fluoro, chloro, bromo, iodo, trifluoromethyl, propargyl, nitro, carbamoyl, ureido, azido, isocyanate, thioisocyanate, hydroxylamino, and nitroso.

26. (Previously Presented) The composition of claim 23 wherein R^3 is methyl or ethyl.

27.-28. (Cancelled)

29. (Currently Amended) The pharmaceutical composition of claim ~~28~~ 23, wherein said pharmaceutically acceptable salts are inorganic acid addition salts, organic acid addition salts, salts with acidic amino acids, and hydrates or solvates thereof with alcohols and other solvents.

30. (Currently Amended) The pharmaceutical composition of claim 29, wherein said ~~analog is an~~ pharmaceutically acceptable salts are inorganic acid addition ~~salt~~ salts selected from the group consisting of hydrochloride, hydrobromide, sulfate, phosphate and nitrate.

31.-32. (Cancelled)

33. (Previously Presented) The pharmaceutical composition of claim 23, wherein the composition blocks an nAChR.

34. (Currently Amended) The pharmaceutical composition of claim ~~31~~ 33, wherein the nAChR is the $\alpha 3\beta 4$ receptor.